2022 Summit of the Thrombosis & Hemostasis Societies of North America Chicago, IL & Online | August 16-18, 2022 Pre-Summit Workshops on August 15 The Thrombosis and Hemostasis Societies of North America (THSNA) will hold its 2022 comprehensive scientific meeting dedicated to thrombosis and hemostasis issues in Chicago, IL from August 16 - 18 including a Pre-Summit Workshop Day on
Read MoreLes professionnels de la santé doivent savoir qu’il existe un risque d’interactions médicamenteuses entre les anticoagulants oraux directs (AOD) et un ingrédient de Paxlovid (le ritonavir) chez les patients traités par un AOD (en particulier l’apixaban et le rivaroxaban) et possiblement admissibles au traitement par Paxlovid, un antiviral contre la COVID-19. Des données probantes indiquent que les patients prenant des
Read MoreIn patients who are receiving a direct oral anticoagulant (DOAC), especially apixaban and rivaroxaban, and may be eligible to receive the antiviral drug Paxlovid for the treatment of COVID-19, health care professionals should be aware of a potential drug-drug interaction between DOACs and a component of Paxlovid (ritonavir). There is evidence that patients who take DOACs and ritonavir at the
Read More
